News

Myotubular myopathy: “Today my son Jules is able to stand”

Suffering from myotubular myopathy, a disease that’s often fatal before the age of 2, Jules received a gene therapy treatment produced by research from Genethon, as part of a clinical trial in January 2020. His progress is spectacular.

(read more)

Pierre, suffering from limb girdle muscular dystrophy: “For me, a cure would mean no more losing”

Pierre is a 14-year-old middle-schooler. Four years ago he received the diagnosis on FKRP limb girdle muscular dystrophy. This progressive disease saps his strength little by little. At Genethon, Isabelle Richard’s team has worked for over 25 years on limb girdle muscular dystrophy. A first gene therapy treatment for Pierre’s disease could… (read more)

Spinal muscular atrophy: for Victoire’s mom, treatment was a magical moment

Suffering from spinal muscular atrophy, Victoire received a gene therapy treatment derived from technologies developed at Genethon. Her mom recounts the anguish of the diagnosis, the immense relief of the treatment and the little girl’s spectacular progress in the weeks following the injection.

(read more)

Preliminary results of clinical trial for rare liver disease Crigler-Najjar syndrome presented at ESGCT congress

After a first presentation at the International Liver Congress last June, new preliminary results have just been presented at the European Society of Geneand Cell Therapy (ESGCT) congress by Dr d’Antiga, one of the investigators of the trial (Bergamo, Italy). Based on initial observations, the drug candidate is well tolerated and the first… (read more)

Cholesterol Metabolism: A Potential Therapeutic Target in Duchenne Muscular Dystrophy

David Israeli, his student Ai Vu Hong PhD, and Fatima Amor, all members of the Progressive Dystrophies laboratory directed by Isabelle Richard at Genethon, have published the results of research offering new perspectives on the treatment of Duchenne muscular dystrophy in the (read more)

Genethon’s teams present their progress at the ASGCT meeting

Limb girdle muscular dystrophies, rare diseases of the liver or production of vectors on a large scale: these are some of the topics presented by Genethon’s teams at the annual meeting of the American Society for Gene and Cell Therapy (ASGCT), to be held virtually from May 11 to 14.

(read more)

Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT 0004 for Duchenne Muscular Dystrophy

Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT 0004 for Duchenne Muscular Dystrophy

(read more)

Genethon, 30 years of pioneering research and innovation in treating rare diseases

On February 28, International Rare Disease Day will put the spotlight on the rare diseases community throughout the world. In France, Genethon, a unique not-for-profit laboratory, innovates to develop gene therapy treatments for rare diseases.

(read more)

Genethon and WhiteLab Genomics join forces to enhance gene therapy through artificial intelligence

WhiteLab Genomics, a specialist in artificial intelligence applied to gene and cell therapies, has signed a partnership agreement with Genethon, a pioneering research center in the field of gene therapy. The alliance will harness the power of artificial intelligence to accelerate development of innovative gene therapies.

(read more)

Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease

Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease, led by the company Spark Therapeutics, using technologies developed at Genethon.

(read more)

Genethon gets the green light from the ANSM to start an innovative gene therapy trial for Duchenne muscular dystrophy

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorisation from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular… (read more)

Genethon welcomes the submission to EMA of Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics, a french biopharma company, just submitted to EMAMarketing Autorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON), a rare, mitochondrial genetic disease, caused by mutation in the ND4 mitochondrial gene.

(read more)

A Genethon team succeeds in inhibiting the immune response linked to AAV, opening up the possibility of treating more patients by gene therapy

A Genethon team, working as part of an international collaboration, published the results of their work in Nature Medicine on June 1, 2020, opening up new perspectives for gene therapy. Using the IdeS enzyme, these researchers succeeded in inhibiting the immune response to AAV, which is caused by antibodies present as a result of… (read more)

Genethon welcomes the conclusive results of a gene therapy trial in Chronic Septic Granulomatosis, a rare disease of the immune system

Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction. Six of the nine patients are free of treatments related to… (read more)

Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy

Following an initial research and development collaboration on an innovative gene therapy product using micro-dystrophin, Genethon and Sarepta Therapeutics are now started a co-development clinical program for Duchenne muscular dystrophy.

(read more)